<DOC>
	<DOCNO>NCT00066872</DOCNO>
	<brief_summary>RATIONALE : Biological therapy imiquimod use different way stimulate immune system stop cancer cell grow . It yet know topical imiquimod effective surgery treat basal cell skin cancer . PURPOSE : This randomized phase III trial study well topical imiquimod work compare surgery treat patient basal cell skin cancer .</brief_summary>
	<brief_title>Topical Imiquimod Compared With Surgery Treating Patients With Basal Cell Skin Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare rate local recurrence 3 year patient nodular superficial basal cell skin cancer treat imiquimod 5 % cream v excisional surgery . - Compare recurrence 6 month 1 , 2 , 5 year patient treat regimen . - Compare time first recurrence patient treat regimen . - Compare aesthetic appearance lesion sit patient treat regimen . - Compare pain patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center lesion type ( nodular vs superficial ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive topical imiquimod single lesion daily 6 week superficial lesion 12 week nodular lesion . Patients early treatment failure recurrence offer surgical excision . - Arm II : Patients undergo surgical excision . Patients follow 6 , 12 , 18 week , every 6 month 1 year , annually 2 year , 5 year . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 500 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary basal cell skin carcinoma Nodular superficial lesion ( ) * Located lowrisk area NOTE : *Any number lesion allow 1 lesion per patient select study No genetic nevoid condition ( e.g. , Gorlin 's syndrome ) No morphoeic ( microinfiltrative ) histology PATIENT CHARACTERISTICS : Age Any age Performance status Not specify Life expectancy Not specify Hematopoietic No bleed disorder Hepatic Not specify Renal Not specify Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month study participation No allergy study interventions No lifethreatening disease Must available study followup 3 year Must access telephone PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No concurrent participation experimental trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>basal cell carcinoma skin</keyword>
</DOC>